TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Early Enteral vs. Parenteral Nutrition on Preservation of Gut Mucosa Integrity in Patients Requiring Mechanical Ventilation and Catecholamine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Invasive mechanical ventilation expected to be required more than 48 hours~* Nutrition started within 24 hours after initiation of endotracheal mechanical ventilation~* Treatment with vasoactive drug administered via a central venous catheter~* Age over 18 years~* Signed information~Exclusion Criteria:~* Abdominal surgery within 1 month before inclusion~* History of esophageal, gastric, duodenal or pancreatic surgery~* Bleeding from the esophagus, stomach or bowel~* enteral nutrition via gastrostomy or jejunostomy~* pregnancy~* Treatment-limitation decisions~* Current inclusion in a trial on comparison between enteral and parenteral nutrition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Parenteral nutrition (Type: OTHER): Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level \< 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
- Enteral nutrition (Type: OTHER): Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Oxygen on Healing an Artery From the Injury of Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-80+/- referred and considered a candidate for a synthetic hemodialysis access graft.~2. Baseline room air arterial blood concentration \>70 and arterial carbon dioxide concentration 45 mmHg. Pulmonary function tests \> 75% predicted values~3. Currently undergoing dialysis~4. No previous synthetic hemodialysis grafts placed in the same arm (fistula in ipsilateral arm permitted)~5. Ability to use 5L/minute supplemental oxygen by nasal cannula~6. Nonsmoker, able to avoid other situations which would constitute a risk for use of oxygen~7. Medical condition with \> 1 year life expectancy~8. Currently on no medications which would interfere with wound healing (i.e. steroids, chemotherapeutic agents)~9. Not pregnant nor planning to become pregnant during study period~Exclusion Criteria:~1. Failure to meet inclusion criteria~2. Failure to comply with study protocol for 3 consecutive days during the 6 wk oxygen/non-oxygen supplement period immediately following graft placement~3. Medical condition developing during study period causing a significantly worsening pulmonary function requiring supplemental oxygen for \> 3 days~4. Need to take medication during study period which would interfere with wound healing any time during the 6 week period immediately following graft placement or need to take chronic medications (\> 6 weeks) during the remainder of the study period.~5. Patient desire to withdraw~6. Failure of evidence of adequate increase in arterial blood oxygen concentration (pa02 \> 115 for oxygen supplemented and pa02 \> 55 mmHg for control obtained from arterial access port during dialysis run~7. Failure to use supplemental oxygen (if in supplemental oxygen group) at least 18 hours per day (as recorded in journal) -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): No exposure to supplemental oxygen
- Oxygen, treatment, supplement (Type: OTHER): 6 weeks of supplemental oxygen delivered by nasal cannula post hemodialysis graft placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological proved diagnosis of gastric cancer.~* Unresectable peritoneal metastases and primary tumor proved at surgery.~* No evidence of distant metastases.~* Have not received radiotherapy, chemotherapy or immunotherapy.~* ECOG score: 0\~2.~* Written informed consent is obtained prior to commencement of trial treatment.~Exclusion Criteria:~* Existence of distant metastasis outside the abdomen.~* Any previous radiotherapy, chemotherapy or immunotherapy.~* Active systemic infections.~* Inadequate cardiac function, renal function, liver function or bone marrow function at the beginning of the trial.~* Female patients who are pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): HIPEC with Docetaxel/ Lobaplatin at the time of fist surgery and twice repeat within one week after the surgery, following 2 cycles of 3-week Oxaliplatin/S1 chemotherapy combined with Apatinib and 1 cycles of 3-week Oxaliplatin/S1 chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~\* Diagnosed with chronic SUNHA~Exclusion Criteria:~\* Other comorbidities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Psilocybin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acute Effects of Gabapentin in Sleep Parameters and Hormonal Release During Sleep in Older Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60 years old or more,~* healthy men~Exclusion Criteria:~* Basal Apnea-Hypopnea index (aHI)\>=15~* Restless Legs Syndrome Symptons~* BMI less than 18.5 kg/m2 or greater than 30 kg/m2~* Less than 30 min. of regular physical activity (at least walking inside home, etc.)~* Plasma albumin below 3.5 mg/dL~* Psychoactive drugs use~* Drugs with muscle anabolic potential~* Current treatment for obesity or weight gain~* Enteral or parenteral feeding~* Inability to walk without assistance,~* Loss of independence in any activity of daily living~* Nocturia above 2 episodes~* Smoking more than 2 cigarettes per day~* Alcoholism (more than 2 doses a day)~* Prior epilepsy diagnosis~* Clinically evident atherosclerotic disease~* Dementia~* Depression~* Rheumatic diseases~* Cancer~* Diabetes (poorly controlled, HbA1C \> 7,0, requirement of insulin)~* Thyroid dysfunction without treatment~* Advanced stages in COPD, HF, liver or renal failure

- Gender: MALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): A single dose of placebo with exactly the same characteristics of the active drug at bedtime.
- Gabapentin (Type: EXPERIMENTAL): A single dose of Gabapentin 300mg at bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Methadone As Co-Opioid Analgesic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individual reporting average pain score for the last 24 hours that is at least a 4 on a numerical scale from 0 to 10 (0= no pain, 10=the worst possible pain) with a history of cancer (active or no evidence of disease).~2. Individual is receiving strong opioids (morphine, fentanyl, oxycodone, hydromorphone) for 3 weeks prior to enrollment.~3. Individual requires at least 150 mg of daily morphine equivalent daily dose for cancer pain. Using the formula MEDD = dose X MEDD Factor (App L) it would be follows: morphine: a 24 hour total oral intake (sum of PRN and around the clock doses) of 150 mg or greater would qualify the patient, for fentanyl alone: a 24 hour total transdermal intake of 75mcg/h or greater would qualify the patient, for oxycodone alone: a 24 hour total oral intake of 100 mg or greater would qualify the patient, and for hydromorphone alone: a 24 hour total oral intake of 30 mg/day or greater would qualify the patient.~4. Individual has the ability to receive morphine or methadone orally.~5. Individual has no known allergy of history of severe toxicity to morphine or methadone.~6. Individual has normal cognition defined as normal state of arousal and absence of obvious clinical findings of confusion, memory or concentration deficit.~7. Individual has adequate renal function (creatinine less or equal to 2.0 MG/DL)~8. Individual has a Zubrod performance status of 3 or lower.~9. Individual is willing to sign written informed consent.~10. Individual is 18 years of age or older.~11. Individual on stable doses(on same dose for at least one week) of nonopioid analgesics including NSAIDS, corticosteroids, gabapentin, pregabalin, or antidepressants prescribed for the purposes of pain control.~Exclusion Criteria:~1. Individual is determined incapable of completing the evaluation forms.~2. Individual with clinically evident impaired cognition.~3. Patient with MEDD greater than 600.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Morphine Only (Type: ACTIVE_COMPARATOR): Morphine - Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain.
- Morphine + Methadone (Type: ACTIVE_COMPARATOR): Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain.~1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Project for Multifidus Muscle Evaluation in Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis by an UAMS neuro-immunologist of relapsing-remitting MS or primary progressive MS or secondary progressive MS~* Age between 18 years old and 50 years old on consent~* Complain of low back pain or severe axial back pain~* English-speaking~Exclusion Criteria:~* Patients that also have the diagnosis of thoracic or lumbar radiculopathy or history of prior thoracic or lumbar spinal surgery.~Patients that are currently pregnant EDSS over 5.5 or less than 1.0 Patient younger than 18 years old or older than 50 years old Knee total extension of less than 100 degrees

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Adult patients \< 50 years old who have multiple sclerosis and back pain who are undergoing home exercise

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of hemophilia A or B~* Either on a stable prophylaxis regimen for their bleeding disorder (factor, bypassing agent, or nonfactor product therapy) OR currently taking or agree to initiate a gastroprotective agent (esomeprazole) for the duration of the trial~* Diagnosis of Hemophilic Arthopathy for at least 6 months prior to screening~* Chronic symptomatic pain in one or more joint(s) on 20 of the 30 days prior to screening.~* Able and willing to wash out of non-study analgesic medications/agents for at least 7 days prior to Randomization including: acetaminophen (paracetamol), NSAIDs, opioids, cannabinoids, topical analgesics, benzodiazepines, gabapentin/pregabalin-containing products and other antiepileptic drugs used for pain~* Primary source of pain is due to Hemophilic Arthropathy~Exclusion Criteria:~* Taking opioids for greater than 4 days per week prior to screening~* Has a history of advanced renal disease or severe liver disease (within the last 6 months)~* Receiving emicizumab while also receiving activated prothrombin complex concentrate (FEIBA)~* Uncontrolled or poorly controlled hypertension~* History of major cardiac or cerebrovascular disease~* History of an upper GI perforation, obstruction, or major GI bleed or current evidence of GI bleeding~* Has active hepatitis C or hepatitis B infection or uncontrolled HIV. Note: Patients who are HIV positive are allowed to participate if considered to be controlled.~* Has a positive drug screen for all prohibited drugs of potential abuse at screening~* Has had an intra-articular injection (within 3 months), initiated physical therapy (within 30 days) or has had orthopedic surgery (within 4 months) prior to screening

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TRM-201 (Rofecoxib) (Type: EXPERIMENTAL): 1 TRM-201 tablet taken orally once daily for 12 weeks in Part I and orally once daily for an additional 52 weeks in Part II
- Placebo (Type: PLACEBO_COMPARATOR): 1 placebo tablet (to match TRM-201) taken orally once daily for 12 weeks in Part I and then 1 TRM-201 tablet taken orally once daily for an additional 52 weeks in Part II

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed metastatic or unresectable melanoma with V600E mutation~* Measurable disease~* May have received prior immunotherapy (excluding interleukin 2)~* Life expectancy greater than 3 months~* Recovered from effects of previous surgery and/or traumatic injury~* Must agree to use effective contraception~Exclusion Criteria:~* Pregnant or breastfeeding~* Psychological, familial or other conditions that could hamper compliance with protocol~* Receiving other study agents~* History of carcinomatous meningitis~* Known active brain metastases~* Have received a BRAF inhibitor~* Uncontrolled intercurrent illness~* HIV positive on antiretroviral therapy~* History of a different malignancy within past 5 years (except cervical cancer in situ or basal/squamous cell carcinoma of the skin)~* Active hepatitis B or C~* Have received allogenic bone marrow transplant or organ transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Oral vemurafenib 960 milligrams twice a day plus intravenous aldesleukin 600,000 IU/kg every eight hours to tolerance (maximum 14 doses) over five days on days 15-19 of cycle 1 and on days 1-5 of cycle 2. (A cycle is 28 days)~The first course of treatment will consist of three 28-day cycles (12 weeks): 2 weeks of lead-in vemurafenib plus 3 weeks on IL-2 plus 7 weeks wait.~A second course may be given at the discretion of the investigator, if there is evidence of tumor stability or regression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects are fully eligible for and have completed the AMYPRED-US (Amyloid Prediction in early stage Alzheimer's disease from acoustic and linguistic patterns of speech) study.~(See https://clinicaltrials.gov/ct2/show/NCT04928976)~- Subject consents to take part in FUTURE extension study.~Exclusion Criteria:~* Subject hasn't completed the full visit day in the AMYPRED-US study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1: MCI amyloid positive (Type: None): * Meet the National Institute of Aging - Alzheimer's Association (NIA-AA) core clinical criteria (2011) for MCI due to Alzheimer's~* Positive amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)
- Arm 2: MCI amyloid negative (Type: None): * Non-AD Mild Cognitive Impairment (MCI)~* Negative amyloid PET or amyloid CSF status.~* MMSE 23-30 (inclusive)
- Arm 3: CN amyloid positive (Type: None): * Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Positive amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)
- Arm 4: CN amyloid negative (Type: None): * Absence of a diagnosis of cognitive disorder and/or subjectively reported cognitive decline~* Negative amyloid PET or amyloid CSF status.~* MMSE 26-30 (inclusive)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a histologically or cytologically confirmed cancer diagnosis for which EGFRI treatment is indicated~* Initiation of topical steroids or control treatment within 3 days of initiation of cetuximab, erlotinib, panitumumab, or afatinib~* Patients must be age ≥ 18 years.~* Life expectancy of greater than 6 weeks~* Patient able to use topical medications reliably and complete questionnaires with assistance if needed~* Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study.~Exclusion Criteria:~* Patients who have used systemic or topical steroids within 7 days of trial registration, or start systemic or topical steroids for reasons unrelated to trial during the 6-week follow up period~* Patients who have used antibiotics within 7 days of trial registration, or start antibiotics for other conditions during the 6-week follow up period~* History of allergic reactions to topical steroids~* Patients with any rash at the time of study registration~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* Patients using any other topical medications in the treatment areas (face, chest, or back).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Patients in Control group will be instructed to follow a daily moisturizer and sunscreen regimen. Erlotinib, cetuximab, panitumumab, or afatinib will be administered as standard of care treatment.
- Triamcinolone (Type: EXPERIMENTAL): Patients in the Triamcinolone group will be applying Triamcinolone 0.1% cream daily to their face, chest, and upper back, in addition to adhering to the same daily moisturizer and sunscreen regimen of the Control group. Erlotinib, cetuximab, panitumumab, or afatinib will be administered concomitantly as standard of care treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* cytologically or histologically verified anaplastic thyroid cancer~* completed standard therapy~* operated with R0 or R1 surgery~* Performance Status 0-2 (if pulmonary mets PS 0-1)~* normal wound healing~* neutrophils \> 1,5 million/ml~* platelets \> 100 million/ml~* bilirubin \< 2 ULN~* creatinin \< 150mikromol/L~Exclusion Criteria:~* PS 3-4 (if pulmonary mets 2-4)~* R2 resection of primary tumor

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chemotherapy (Type: EXPERIMENTAL): Treatment with Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy